Private Wealth Partners LLC Acquires Shares of 5,950 Novo Nordisk A/S (NYSE:NVO)

Private Wealth Partners LLC acquired a new position in Novo Nordisk A/S (NYSE:NVO - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 5,950 shares of the company's stock, valued at approximately $616,000.

Other institutional investors have also added to or reduced their stakes in the company. Valmark Advisers Inc. boosted its stake in Novo Nordisk A/S by 82.4% in the fourth quarter. Valmark Advisers Inc. now owns 5,257 shares of the company's stock valued at $544,000 after acquiring an additional 2,375 shares during the last quarter. Addison Advisors LLC boosted its stake in Novo Nordisk A/S by 12.3% in the fourth quarter. Addison Advisors LLC now owns 2,331 shares of the company's stock valued at $241,000 after acquiring an additional 255 shares during the last quarter. Headlands Technologies LLC boosted its stake in Novo Nordisk A/S by 33.1% in the fourth quarter. Headlands Technologies LLC now owns 2,857 shares of the company's stock valued at $296,000 after acquiring an additional 711 shares during the last quarter. Citizens Financial Group Inc. RI boosted its stake in Novo Nordisk A/S by 1.8% in the fourth quarter. Citizens Financial Group Inc. RI now owns 13,703 shares of the company's stock valued at $1,418,000 after acquiring an additional 239 shares during the last quarter. Finally, Truist Financial Corp boosted its stake in Novo Nordisk A/S by 1.6% in the fourth quarter. Truist Financial Corp now owns 597,059 shares of the company's stock valued at $61,766,000 after acquiring an additional 9,450 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on NVO. BMO Capital Markets began coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They set an "outperform" rating and a $163.00 price target on the stock. UBS Group began coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 16th. They set a "neutral" rating on the stock. Cantor Fitzgerald restated an "overweight" rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. Finally, Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an "overweight" rating and a $120.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of "Moderate Buy" and a consensus price target of $133.60.

Novo Nordisk A/S Price Performance

NYSE NVO traded up $1.06 on Friday, hitting $126.85. The stock had a trading volume of 3,312,457 shares, compared to its average volume of 3,307,405. Novo Nordisk A/S has a 52-week low of $75.56 and a 52-week high of $138.28. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82. The company has a market capitalization of $569.24 billion, a price-to-earnings ratio of 46.89, a price-to-earnings-growth ratio of 2.12 and a beta of 0.41. The firm has a 50-day moving average of $126.86 and a 200-day moving average of $112.21.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The business had revenue of $9.51 billion for the quarter, compared to analysts' expectations of $9.14 billion. Equities analysts expect that Novo Nordisk A/S will post 3.32 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were issued a $0.664 dividend. This is a positive change from Novo Nordisk A/S's previous Semi-Annual dividend of $0.22. The ex-dividend date of this dividend was Friday, March 22nd. This represents a dividend yield of 0.9%. Novo Nordisk A/S's dividend payout ratio is presently 49.17%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.